NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ORKA

Oruka Therapeutics Inc

May 16 • 04:00PM ET

10.06

Dollar change +0.60
Percentage change 6.34	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF IBB ITOT IWC IBBQ BIB ISCB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.27	Insider Own	15.35%	Shs Outstand	37.44M	Perf Week	5.45%
Market Cap	376.65M	Forward P/E	-	EPS next Y	-2.41	Insider Trans	2.18%	Shs Float	31.69M	Perf Month	16.84%
Income	-78.08M	PEG	-	EPS next Q	-0.48	Inst Own	75.33%	Short Float	8.41%	Perf Quarter	-10.02%
Sales	0.00M	P/S	-	EPS this Y	44.22%	Inst Trans	35.04%	Short Ratio	10.35	Perf Half Y	-61.46%
Book/sh	9.66	P/B	1.04	EPS next Y	-11.49%	ROA	-37.74%	Short Interest	2.66M	Perf Year	-53.05%
Cash/sh	9.32	P/C	1.08	EPS next 5Y	13.86%	ROE	-39.06%	52W Range	5.49 - 33.00	Perf YTD	-48.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.88%	ROI	-21.37%	52W High	-69.52%	Beta	-0.42
Dividend TTM	-	Quick Ratio	30.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	83.41%	ATR (14)	0.89
Dividend Ex-Date	Aug 26, 2024	Current Ratio	30.03	EPS Y/Y TTM	-5.74%	Oper. Margin	-	RSI (14)	52.77	Volatility	9.67% 9.04%
Employees	28	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	38.86
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	69.70%	Payout	-	Rel Volume	0.36	Prev Close	9.46
Sales Surprise	-	EPS Surprise	21.31%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	257.33K	Price	10.06
SMA20	0.74%	SMA50	0.13%	SMA200	-44.47%	Trades		Volume	92,459	Change	6.34%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-25	Initiated	Wolfe Research	Outperform	$20
Oct-11-24	Initiated	Stifel	Buy	$49
Oct-07-24	Initiated	H.C. Wainwright	Buy	$45
Sep-17-24	Initiated	Leerink Partners	Outperform	$44
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy	$40
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy	$2
Oct-09-13	Initiated	Dawson James	Buy	$3.75

May-14-25 04:15PM	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 07:00AM	Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference (GlobeNewswire)
Mar-07-25 08:30AM	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-06-25 04:09PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 07:00AM	Oruka Therapeutics to Present at Multiple March Investor Conferences (GlobeNewswire)
07:15AM	Loading…
Dec-20-24 07:15AM	Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 (TipRanks)
Dec-19-24 07:00AM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody (GlobeNewswire)
Dec-18-24 07:00AM	Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Nov-19-24 08:00AM	Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference (GlobeNewswire) +5.54%
Nov-13-24 04:25PM	Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.43%
Nov-04-24 07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Sep-25-24 07:08AM	Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-12-24 07:05AM	Oruka Therapeutics Announces $200 Million Private Placement (GlobeNewswire) -12.22%
07:00AM	Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 (GlobeNewswire)
Sep-03-24 07:00AM	Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million (GlobeNewswire) -11.46%
04:50PM	Loading…
Aug-29-24 04:50PM	ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split (GlobeNewswire) +33.19%
Aug-26-24 07:30PM	ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) -8.41%
Aug-23-24 04:30PM	ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +6.12%
Aug-16-24 04:15PM	ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +21.36%
Aug-01-24 04:15PM	ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.07%
Jun-28-24 02:16AM	Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)? (Insider Monkey) +6.39%
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey)
May-14-24 01:48PM	3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally (InvestorPlace)
Apr-25-24 09:55PM	ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024 (InvestorPlace)
04:15PM	ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-03-24 02:30PM	Why Is ARCA Biopharma (ABIO) Stock Up 85% Today? (InvestorPlace) +90.06%
12:00PM	Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details (Benzinga)
07:30AM	ARCA biopharma and Oruka Therapeutics Announce Merger Agreement (GlobeNewswire)
Feb-01-24 04:35PM	ARCA biopharma Announces 2023 Financial Results (GlobeNewswire)
Oct-18-23 04:25PM	ARCA biopharma Announces Third Quarter 2023 Financial Results (GlobeNewswire)
04:25PM	Loading…
Jul-21-23 04:25PM	ARCA biopharma Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 11:30AM	We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Apr-24-23 04:25PM	ARCA biopharma Announces First Quarter 2023 Financial Results (GlobeNewswire)
Feb-24-23 04:20PM	ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-03-23 10:19AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-19-22 04:05PM	James Flynn Joins ARCA biopharma Board of Directors (GlobeNewswire)
Nov-14-22 09:24AM	One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year (Simply Wall St.)
Oct-28-22 04:15PM	ARCA biopharma Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	ARCA biopharma Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-18-22 06:14AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-21-22 04:05PM	Jacob Ma-Weaver Joins ARCA biopharma Board of Directors (GlobeNewswire) +5.56%
May-05-22 04:15PM	ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review (GlobeNewswire) -5.79%
May-02-22 04:15PM	ARCA biopharma Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 04:30PM	ARCA biopharma Establishes Special Committee of the Board of Directors (GlobeNewswire)
Apr-05-22 01:35AM	Albioma : Governance changes (GlobeNewswire)
Apr-01-22 07:09AM	ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Mar-31-22 04:15PM	ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial (GlobeNewswire)
Mar-14-22 04:15PM	ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 04:30PM	Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results (GlobeNewswire)
Feb-08-22 04:21AM	We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Jan-04-22 08:30AM	Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 (GlobeNewswire)
Dec-02-21 08:30AM	ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 (GlobeNewswire)
Nov-20-21 07:01AM	ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week (Simply Wall St.)
Nov-09-21 04:15PM	ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th (GlobeNewswire)
Nov-02-21 04:15PM	ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-21 07:03AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:26AM	ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged (Benzinga)
Oct-28-21 04:30PM	ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data (GlobeNewswire)
Sep-16-21 08:30AM	ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire)
Aug-16-21 08:05AM	ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th (GlobeNewswire) -5.14%
Aug-12-21 01:15AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-21 08:00AM	ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 (GlobeNewswire)
Aug-04-21 04:15PM	ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.44%
Jul-28-21 08:00AM	Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology (GlobeNewswire)
Jul-13-21 08:00AM	ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire) -14.09%
Jul-09-21 08:00AM	ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th (GlobeNewswire) +5.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) -6.95%
Jul-07-21 08:00AM	ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement (GlobeNewswire) +9.36%
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
May-11-21 04:15PM	ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-21 04:05PM	Christopher Graybill Joins ARCA as Vice President, Clinical Development (GlobeNewswire)
May-03-21 04:30PM	ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer (GlobeNewswire)
Mar-18-21 04:30PM	ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-13-21 01:09AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-15-20 08:30AM	ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 (GlobeNewswire)
Dec-09-20 05:40PM	ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders (GlobeNewswire)
Nov-23-20 12:28PM	ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment (MarketWatch) +7.46%
08:30AM	AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation (GlobeNewswire)
Nov-02-20 08:30AM	ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) +5.19%
Oct-07-20 08:30AM	ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 (GlobeNewswire) -8.49%
Oct-05-20 04:30PM	ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality (GlobeNewswire) +12.61%
Sep-21-20 08:00AM	ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 (GlobeNewswire) -10.62%
Aug-17-20 08:49AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-12-20 08:00AM	ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19 (ACCESSWIRE) -7.51%
Aug-05-20 04:15PM	Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-07-20 08:30AM	SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators (GlobeNewswire)
Jun-03-20 09:56AM	ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering (GlobeNewswire) -5.39%
09:56AM	Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More (Zacks)
Jun-01-20 08:20AM	ARCA Biopharma Announces $9.4 Million Registered Direct Offering (GlobeNewswire) -26.98%
May-29-20 12:24PM	A Mighty May: Over $200,000 In Gross Profits (Benzinga) -34.41%
09:59AM	Company News for May 29, 2020 (Zacks)
May-28-20 04:19PM	Arca Biopharma Nearly Quintuples On Plans To Test A Coronavirus Drug (Investor's Business Daily) +386.33%
12:14PM	Arca Biopharma Stock Triples On Plans To Test A Coronavirus Treatment (Investor's Business Daily)
10:27AM	Price Over Earnings Overview: ARCA biopharma (Benzinga)
08:00AM	ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy (GlobeNewswire)
May-07-20 08:30AM	Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions (GlobeNewswire)
May-06-20 04:30PM	ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update (GlobeNewswire)
Feb-18-20 04:30PM	ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-01-20 08:31AM	Does Market Volatility Impact ARCA biopharma, Inc.'s (NASDAQ:ABIO) Share Price? (Simply Wall St.)
Nov-06-19 04:10PM	ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update (GlobeNewswire)

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venrock Healthcare Capital Par	10% Owner	Feb 14 '25	Buy	11.44	88,794	1,015,803	4,148,428	Feb 27 06:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 13 '25	Buy	11.63	14,950	173,868	4,059,634	Feb 27 06:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 12 '25	Buy	11.86	8,971	106,396	4,044,684	Feb 27 06:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 11 '25	Buy	10.95	9,593	105,043	4,035,713	Feb 27 06:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 10 '25	Buy	10.90	574	6,257	4,026,120	Feb 27 06:42 PM
JANUS HENDERSON GROUP PLC	10% Owner	Aug 16 '24	Buy	2.93	5,818	17,067	2,117,213	Aug 20 02:23 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 24 '24	Buy	3.20	189,856	606,873	2,081,168	Jul 26 10:50 AM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 25 '24	Buy	3.05	30,227	92,292	2,111,395	Jul 26 10:50 AM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 03 '24	Buy	3.55	166,042	589,565	1,648,577	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 11 '24	Buy	3.45	94,537	326,304	1,891,312	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 10 '24	Buy	3.46	55,463	192,130	1,796,775	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 08 '24	Buy	3.46	47,492	164,190	1,724,395	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 05 '24	Buy	3.43	28,326	97,065	1,676,903	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 09 '24	Buy	3.43	16,917	58,091	1,741,312	Jul 12 07:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORKA

Oruka Therapeutics Inc

Upgrade your FINVIZ experience